Uridine prevents fenofibrate-induced fatty liver

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Le, Thuc T ^a,b   Urasaki, Yasuyo ^a,b   Pizzorno, Giuseppe ^a,b  

^a NEVADA CANCER INSTITUTE   (United States)

^b DESERT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A REDUCTASE 1; FENOFIBRATE; LONG CHAIN FATTY ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG; URIDINE; VERY LONG CHAIN FATTY ACID; ACYL COENZYME A OXIDASE; ANTILIPEMIC AGENT; FATTY ACID; PEROXISOMAL BIFUNCTIONAL ENZYME; PROTECTIVE AGENT;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FATTY LIVER; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ACYL-COA OXIDASE; ANIMALS; BIOLOGICAL TRANSPORT; FATTY ACIDS; FATTY LIVER; FENOFIBRATE; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NAD; OXIDATION-REDUCTION; PEROXISOMAL BIFUNCTIONAL ENZYME; PROTECTIVE AGENTS; URIDINE;

EID: 84899800137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087179     Document Type: Article

References (61)

1. Connolly GP, Duley JA (1999) Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 20: 218-225.
2. Yamamoto T, Koyama H, Kurajoh M, Shoji T, Tsutsumi Z, et al. (2011) Biochemistry of uridine in plasma. Clin Chim Acta 412: 1712-1724.
3. Saydoff JA, Olariu A, Sheng J, Hu Z, Li Q, et al. (2013) Uridine Prodrug Improves Memory in Tg2576 and TAPP Mice and Reduces Pathological Factors associated with Alzheimer's Disease in Related Models. J Alzheimers Dis.
4. Wurtman RJ, Cansev M, Sakamoto T, Ulus I (2010) Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev 68 Suppl 2: S88-101.
5. Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, et al. (2013) Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J Lipid Res 54: 1044-1057.
6. Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G (2005) Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 280: 21169-21175. (Pubitemid 40805678)
7. Gasser T, Moyer JD, Handschumacher RE (1981) Novel single-pass exchange of circulating uridine in rat liver. Science 213: 777-778. (Pubitemid 11016458)
8. Traut TW, Jones ME (1996) Uracil metabolism - UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol 53: 1-78.
9. Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140: 1-22.
10. Grieco A, Forgione A, Miele L, Vero V, Greco AV, et al. (2005) Fatty liver and drugs. Eur Rev Med Pharmacol Sci 9: 261-263. (Pubitemid 41387388)
11. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54: 773-794.
12. Dykens JA, Will Y (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12: 777-785. (Pubitemid 47362789)
13. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349: 474-485.
14. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM (2008) Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 44: 1259-1272.
15. Fromenty B, Pessayre D (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67: 101-154.
16. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845.
17. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332: 1519-1523.
18. Adams LA, Angulo P (2006) Treatment of non-alcoholic fatty liver disease. Postgrad Med J 82: 315-322. (Pubitemid 43780662)
19. Le TT, Ziemba A, Urasaki Y, Brotman S, Pizzorno G (2012) Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-Stokes Raman scattering microscopy. PLoS One 7: e51092.
20. Balfour JA, McTavish D, Heel RC (1990) Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40: 260-290.
21. Keating GM (2011) Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 11: 227-247.
22. McKeage K, Keating GM (2011) Fenofibrate: a review of its use in dyslipidaemia. Drugs 71: 1917-1946.
23. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, et al. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
24. Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, et al. (2009) Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 284: 34036-34044.
25. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, et al. (2009) Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 37: 521-535.
26. Brunmair B, Lest A, Staniek K, Gras F, Scharf N, et al. (2004) Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 311: 109-114. (Pubitemid 39287789)
27. Reddy JK, Azarnoff DL, Hignite CE (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283: 397-398.
28. Peters JM, Shah YM, Gonzalez FJ (2012) The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12: 181-195.
29. Le TT, Yue S, Cheng JX (2010) Shedding new light on lipid biology with coherent anti-Stokes Raman scattering microscopy. J Lipid Res 51: 3091-3102.
30. Evans CL, Xie XS (2008) Coherent Anti-Stokes Raman Scattering Microscopy: Chemically Selective Imaging for Biology and Medicine. Annu Rev Anal Chem 1: 883-909.
31. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, et al. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093. (Pubitemid 28512236)
32. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, et al. (1999) Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 45: 100-110. (Pubitemid 29036438)
33. Weller S, Gould SJ, Valle D (2003) Peroxisome biogenesis disorders. Annu Rev Genomics Hum Genet 4: 165-211. (Pubitemid 37392923)
34. Reddy JK, Hashimoto T (2001) Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 21: 193-230. (Pubitemid 32695270)
35. Fritz KS, Galligan JJ, Hirschey MD, Verdin E, Petersen DR (2012) Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. J Proteome Res 11: 1633-1643.
36. Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489-503. (Pubitemid 351767117)
37. Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393-416. (Pubitemid 38316578)
38. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, et al. (2007) Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27: 8807-8814.
39. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, et al. (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121-125.
40. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, et al. (2011) SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 44: 177-190.
41. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435. (Pubitemid 39050375)
42. He W, Newman JC, Wang MZ, Ho L, Verdin E (2012) Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab 23: 467-476.
43. Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA (2007) Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 45: 72-79. (Pubitemid 46144366)
44. Saydoff JA, Liu LS, Garcia RA, Hu Z, Li D, et al. (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res 994: 44-54. (Pubitemid 37452436)
45. Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, et al. (2012) Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc 7: 1068-1085.
46. Liou HL, Storch J (2001) Role of surface lysine residues of adipocyte fatty acid-binding protein in fatty acid transfer to phospholipid vesicles. Biochemistry 40: 6475-6485.
47. Anderson KA, Hirschey MD (2012) Mitochondrial protein acetylation regulates metabolism. Essays Biochem 52: 23-35.
48. Paik WK, Pearson D, Lee HW, Kim S (1970) Nonenzymatic acetylation of histones with acetyl-CoA. Biochim Biophys Acta 213: 513-522.
49. Schwer B, North BJ, Frye RA, Ott M, Verdin E (2002) The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 158: 647-657. (Pubitemid 34920104)
50. Scher MB, Vaquero A, Reinberg D (2007) SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 21: 920-928. (Pubitemid 46625641)
51. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP (2008) SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 28: 6384-6401.
52. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP (2002) SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A 99: 13653-13658. (Pubitemid 35215436)
53. Bao J, Lu Z, Joseph JJ, Carabenciov D, Dimond CC, et al. (2010) Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. J Cell Biochem 110: 238-247.
54. Zhao S, Xu W, Jiang W, Yu W, Lin Y, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004.
55. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607-618. (Pubitemid 44205490)
56. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, et al. (2011) Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 433: 505-514.
57. Xiong Y, Guan KL (2012) Mechanistic insights into the regulation of metabolic enzymes by acetylation. J Cell Biol 198: 155-164.
58. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13: 29-83.
59. Urasaki Y, Johlfs MG, Fiscus RR, Le TT (2012) Imaging immune and metabolic cells of visceral adipose tissues with multimodal nonlinear optical microscopy. PLoS One 7: e38418.
60. Samburova V, Lemos MS, Hiibel S, Hoekman SK, Cushman JC, et al. (2013) Analysis of Triacylglycerols and Free Fatty Acids in Algae Using Ultra-Performance Liquid Chromatography Mass Spectrometry. J Am Oil Chem Soc 90: 53-64.
61. Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2: 287-295. (Pubitemid 47040043)